May 25, 2026
This study tests whether a drug called duvakitug can help people with moderate-to-severe ulcerative colitis stay in remission long-term. Participants will receive either the drug or a placebo for 40 weeks, with an option to continue in an extended study for up to 6 years. The trial will measure how well the drug prevents flare-ups and what side effects occur.
Who qualifies: Ages 16–80, any sex, with moderately to severely active ulcerative colitis
Where: Coronado, CA; Colorado Springs, CO; Fort Myers, FL
Contact: Trial Transparency email recommended (Toll free for US & Canada) · 800-633-1610
This study watches how a drug called filgotinib (brand name Jyseleca) performs in real-world conditions for people with ulcerative colitis in Korea. Researchers will track any side effects, unexpected reactions, and how well the drug works when used as prescribed. This is a post-approval study to make sure the drug is safe and effective for Korean patients.
Who qualifies: Ages 18+, any sex, with ulcerative colitis in Korea
Where: Cheonan, Chuncheon, and Wŏnju, South Korea
Contact: Serena SoYoun Kwon · +82-2-3451-5533
This study tests whether a drug called vorinostat can reduce inflammation in moderate-to-severe Crohn's disease that isn't responding to current treatments. Participants who respond well will then continue treatment and eventually move to a 2-year maintenance phase with a drug called ustekinumab. The study spans several phases over multiple years and includes regular clinic visits, blood tests, and symptom tracking.
Who qualifies: Ages 18–65, any sex, with moderate-to-severe Crohn's disease not controlled by medicine
Where: Bethesda, MD
Contact: Ivan J Fuss, M.D. · (301) 761-7091
Biochemical and Biophysical Research Communications, 2025 · Wang X et al.
Key takeaway
Magnolia officinalis, a traditional herbal remedy for diarrhea and cramping, is now being studied with modern tools to understand exactly how it works. If you're exploring herbal options for IBS-D, this research helps explain why some people report symptom relief and identifies the active compounds worth paying attention to.
Researchers used machine learning and network analysis to identify which compounds in Magnolia bark are actually responsible for reducing IBS-D symptoms. They found that the herb works through multiple targets in the body—not just one mechanism—which explains why it may help several different symptoms at once, from diarrhea to abdominal pain.
Read on PubMed →Journal of Medical Internet Research, 2025 · Xu X et al.
Key takeaway
If you don't have easy access to a gastroenterologist or prefer managing IBS on your own schedule, internet-based self-help programs—like cognitive behavioral therapy or stress management apps—are backed by evidence and can actually improve your symptoms.
Researchers reviewed multiple randomized controlled trials testing online self-help programs for IBS and combined the results to see which ones work best. They found that internet-based interventions targeting behavioral and psychological factors do lead to meaningful improvements in IBS symptoms and quality of life.
Read on PubMed →Naunyn-Schmiedeberg's Archives of Pharmacology, 2025 · Rejili M et al.
Key takeaway
If you've been prescribed duloxetine (Cymbalta) for IBS pain, it's not just working as an antidepressant—it actually rebalances your gut-brain communication, reduces immune inflammation in the gut, and may even shift your microbiota. Understanding this can help you see why it may take several weeks to notice improvement.
This review examines how duloxetine, a medication sometimes prescribed for IBS pain, works beyond just mood effects. It targets the gut-brain axis by calming nerve signals, reducing inflammatory responses in the intestines, and potentially changing your microbiota composition—making it particularly useful for pain-dominant IBS.
Read on PubMed →